Marinomed Biotech AG Launches New Eye Drops in Austria

Marinomed Biotech AG has introduced its new moisturizing Carragelose eye drops, marketed as “Coldamaris protect,” in Austria. This product aims to treat dry eyes, expanding Marinomed's Carragelose product line, which includes various nasal sprays and throat products. These eye drops are noteworthy for achieving a 54% improvement in dry-eye symptoms in a clinical trial while maintaining a favorable safety profile.

This launch aligns with Marinomed's recent licensing deal with Sigmapharm and supports the company's earn-out milestones agreed upon with Unither Pharmaceuticals, following the latter's acquisition of the Carragelose business in 2024. In parallel, Marinomed has progressed in conforming its Carragelose products to the EU's new medical device regulation standards, ensuring their continued compliance and safety.